Résumé des caractéristiques du produit - DAPTOMYCINE ACCORD 350 mg, poudre pour solution injectable/pour perfusion - Base de données publique des médicaments [Internet]. [cited 2023 Jan 24]. Available from: https://base-donnees-publique.medicaments.gouv.fr/affichageDoc.php?specid=69082149&typedoc=R
Benvenuto M, Benziger DP, Yankelev S, Vigliani G. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother. 2006;50:3245–9.
Article CAS PubMed PubMed Central Google Scholar
Jones TW, Jun AH, Michal JL, Olney WJ. High-dose daptomycin and clinical applications. Ann Pharmacother. 2021;55:1363–78.
Article CAS PubMed PubMed Central Google Scholar
Safdar N, Andes D, Craig WA. In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother. 2004;48:63–8.
Article CAS PubMed PubMed Central Google Scholar
Falcone M, Russo A, Cassetta MI, Lappa A, Tritapepe L, d’Ettorre G, et al. Variability of pharmacokinetic parameters in patients receiving different dosages of daptomycin: is therapeutic drug monitoring necessary? J Infect Chemother. 2013;19:732–9.
Article CAS PubMed Google Scholar
Bhavnani SM, Rubino CM, Ambrose PG, Drusano GL. Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. Clin Infect Dis Off Publ Infect Dis Soc Am. 2010;50:1568–74.
Dvorchik BH, Damphousse D. The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects. J Clin Pharmacol. 2005;45:48–56.
Article CAS PubMed Google Scholar
Pai MP, Norenberg JP, Anderson T, Goade DW, Rodvold KA, Telepak RA, et al. Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin. Antimicrob Agents Chemother. 2007;51:2741–7.
Article CAS PubMed PubMed Central Google Scholar
Chagnac A, Weinstein T, Korzets A, Ramadan E, Hirsch J, Gafter U. Glomerular hemodynamics in severe obesity. Am J Physiol-Ren Physiol. 2000;278:F817–22.
Butterfield-Cowper JM, Lodise TP, Pai MP. A fixed versus weight-based dosing strategy of daptomycin may improve safety in obese adults. Pharmacotherapy. 2018;38:981–5.
Article CAS PubMed Google Scholar
Dvorchik B, Arbeit RD, Chung J, Liu S, Knebel W, Kastrissios H. Population pharmacokinetics of daptomycin. Antimicrob Agents Chemother. 2004;48:2799–807.
Article CAS PubMed PubMed Central Google Scholar
Garreau R, Bricca R, Gagnieu M-C, Roux S, Conrad A, Bourguignon L, et al. Population pharmacokinetics of daptomycin in patients with bone and joint infection: minimal effect of rifampicin co-administration and confirmation of a sex difference. J Antimicrob Chemother. 2021;76:1250–7.
Article CAS PubMed Google Scholar
Woillard J-B, Labriffe M, Prémaud A, Marquet P. Estimation of drug exposure by machine learning based on simulations from published pharmacokinetic models: the example of tacrolimus. Pharmacol Res. 2021;167: 105578.
Article CAS PubMed Google Scholar
Ponthier L, Ensuque P, Destere A, Marquet P, Labriffe M, Jacqz-Aigrain E, et al. Optimization of vancomycin initial dose in term and preterm neonates by machine learning. Pharm Res. 2022;39:2497–506.
Article CAS PubMed Google Scholar
Elmokadem A, Riggs MM, Baron KT. Quantitative systems pharmacology and physiologically-based pharmacokinetic modeling with mrgsolve: a hands-on tutorial. CPT Pharmacomet Syst Pharmacol. 2019;8:883–93.
Wickham H, Averick M, Bryan J, Chang W, McGowan LD, François R, et al. Welcome to the tidyverse. J Open Source Softw. 2019;4:1686.
Kuhn M, Wickham H. Tidymodels: a collection of packages for modeling and machine learning using tidyverse principles. [Internet]. 2020. Available from: https://www.tidymodels.org
Tuloup V, Millet A, Taricco A, Parant F, Ferry T, Goutelle S. Evaluation of limited sampling strategies for bayesian estimation of daptomycin area under the concentration-time curve: a short communication. Ther Drug Monit. 2023;45:562–5.
Article CAS PubMed Google Scholar
Chaves RL, Chakraborty A, Benziger D, Tannenbaum S. Clinical and pharmacokinetic considerations for the use of daptomycin in patients with Staphylococcus aureus bacteraemia and severe renal impairment. J Antimicrob Chemother. 2014;69:200–10.
Article CAS PubMed Google Scholar
Labriffe M, Woillard J, Debord J, Marquet P. Machine learning algorithms to estimate everolimus exposure trained on simulated and patient pharmacokinetic profiles. CPT Pharmacomet Syst Pharmacol. 2022;11:1018–28.
留言 (0)